Atopic dermatitis (AD) is a chronic, inflammatory skin disease with heterogeneous and persistent symptoms (particularly pruritus) that profoundly compromise health-related quality of life (HRQL).

Rocatinlimab has demonstrated significant and progressive improvement in multiple measures of clinical severity compared with placebo in adults with moderate-to-severe AD.

This analysis used baseline data from a phase 2 study to develop a deeper understanding of the burden of AD, and to generate a detailed and confirmatory assessment of the impact of rocatinlimab on patient-reported pruritus, sleep, and HRQL.

The benefit of rocatinlimab treatment on patient-reported pruritus, sleep, and HRQL is rapid and is maintained off-treatment for at least 20 weeks following treatment completion.

Assessment of treatment benefit should include the burden of moderate-to-severe AD alongside clinical disease measures in order to develop a full picture.